Virus combinations and chemotherapy for the treatment of human cancers

Shaji K Kumar, L. Gao, B. Yeagy, T. Reid

Research output: Contribution to journalArticle

72 Citations (Scopus)

Abstract

Oncolytic viruses possess an inherent trophism for tumor cells or have been engineered in a variety of ways to selectively replicate in and destroy cancer cells. Because of the unique mode of tumor destruction, oncolytic virotherapy has the potential to augment the antineoplastic activity of chemotherapy and radiation therapy. Many oncolytic viruses, such as adenovirus, HSV, vaccinia, measles, reovirus, Newcastle disease virus and coxsackie virus, have entered into clinical trials and their efficacy and safety have been demonstrated with few, minor, side effects. Data obtained from several clinical trials of the oncolytic adenovirus, ONYX-015, in patients with cancer have been described in detail. Some preclinical studies of oncolytic viruses have demonstrated promising results, mainly when administered in combination with chemotherapeutic drugs. In this review, the clinical use of oncolytic viruses in combination with chemotherapy and radiation therapy, and future directions to enhance the efficacy of oncolytic virotherapy, are discussed.

Original languageEnglish (US)
Pages (from-to)371-379
Number of pages9
JournalCurrent Opinion in Molecular Therapeutics
Volume10
Issue number4
StatePublished - Aug 2008
Externally publishedYes

Fingerprint

Oncolytic Viruses
Combination Drug Therapy
Oncolytic Virotherapy
Viruses
Adenoviridae
Neoplasms
Radiotherapy
Clinical Trials
Vaccinia
Newcastle disease virus
Enterovirus
Measles
Therapeutics
Antineoplastic Agents
Safety
Drug Therapy
Pharmaceutical Preparations

Keywords

  • 5-FU
  • Chemotherapy
  • Cis-platinum
  • Oncolytic virus
  • ONYX-015
  • Virotherapy

ASJC Scopus subject areas

  • Genetics
  • Genetics(clinical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Virus combinations and chemotherapy for the treatment of human cancers. / Kumar, Shaji K; Gao, L.; Yeagy, B.; Reid, T.

In: Current Opinion in Molecular Therapeutics, Vol. 10, No. 4, 08.2008, p. 371-379.

Research output: Contribution to journalArticle

@article{fd5bd36a43b4465abb01c588c59b92f4,
title = "Virus combinations and chemotherapy for the treatment of human cancers",
abstract = "Oncolytic viruses possess an inherent trophism for tumor cells or have been engineered in a variety of ways to selectively replicate in and destroy cancer cells. Because of the unique mode of tumor destruction, oncolytic virotherapy has the potential to augment the antineoplastic activity of chemotherapy and radiation therapy. Many oncolytic viruses, such as adenovirus, HSV, vaccinia, measles, reovirus, Newcastle disease virus and coxsackie virus, have entered into clinical trials and their efficacy and safety have been demonstrated with few, minor, side effects. Data obtained from several clinical trials of the oncolytic adenovirus, ONYX-015, in patients with cancer have been described in detail. Some preclinical studies of oncolytic viruses have demonstrated promising results, mainly when administered in combination with chemotherapeutic drugs. In this review, the clinical use of oncolytic viruses in combination with chemotherapy and radiation therapy, and future directions to enhance the efficacy of oncolytic virotherapy, are discussed.",
keywords = "5-FU, Chemotherapy, Cis-platinum, Oncolytic virus, ONYX-015, Virotherapy",
author = "Kumar, {Shaji K} and L. Gao and B. Yeagy and T. Reid",
year = "2008",
month = "8",
language = "English (US)",
volume = "10",
pages = "371--379",
journal = "Current Opinion in Molecular Therapeutics",
issn = "1464-8431",
publisher = "Current Drugs Ltd.",
number = "4",

}

TY - JOUR

T1 - Virus combinations and chemotherapy for the treatment of human cancers

AU - Kumar, Shaji K

AU - Gao, L.

AU - Yeagy, B.

AU - Reid, T.

PY - 2008/8

Y1 - 2008/8

N2 - Oncolytic viruses possess an inherent trophism for tumor cells or have been engineered in a variety of ways to selectively replicate in and destroy cancer cells. Because of the unique mode of tumor destruction, oncolytic virotherapy has the potential to augment the antineoplastic activity of chemotherapy and radiation therapy. Many oncolytic viruses, such as adenovirus, HSV, vaccinia, measles, reovirus, Newcastle disease virus and coxsackie virus, have entered into clinical trials and their efficacy and safety have been demonstrated with few, minor, side effects. Data obtained from several clinical trials of the oncolytic adenovirus, ONYX-015, in patients with cancer have been described in detail. Some preclinical studies of oncolytic viruses have demonstrated promising results, mainly when administered in combination with chemotherapeutic drugs. In this review, the clinical use of oncolytic viruses in combination with chemotherapy and radiation therapy, and future directions to enhance the efficacy of oncolytic virotherapy, are discussed.

AB - Oncolytic viruses possess an inherent trophism for tumor cells or have been engineered in a variety of ways to selectively replicate in and destroy cancer cells. Because of the unique mode of tumor destruction, oncolytic virotherapy has the potential to augment the antineoplastic activity of chemotherapy and radiation therapy. Many oncolytic viruses, such as adenovirus, HSV, vaccinia, measles, reovirus, Newcastle disease virus and coxsackie virus, have entered into clinical trials and their efficacy and safety have been demonstrated with few, minor, side effects. Data obtained from several clinical trials of the oncolytic adenovirus, ONYX-015, in patients with cancer have been described in detail. Some preclinical studies of oncolytic viruses have demonstrated promising results, mainly when administered in combination with chemotherapeutic drugs. In this review, the clinical use of oncolytic viruses in combination with chemotherapy and radiation therapy, and future directions to enhance the efficacy of oncolytic virotherapy, are discussed.

KW - 5-FU

KW - Chemotherapy

KW - Cis-platinum

KW - Oncolytic virus

KW - ONYX-015

KW - Virotherapy

UR - http://www.scopus.com/inward/record.url?scp=49249131785&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=49249131785&partnerID=8YFLogxK

M3 - Article

C2 - 18683102

AN - SCOPUS:49249131785

VL - 10

SP - 371

EP - 379

JO - Current Opinion in Molecular Therapeutics

JF - Current Opinion in Molecular Therapeutics

SN - 1464-8431

IS - 4

ER -